

# New Zealand Data Sheet



## 1. PRODUCT NAME

---

Ozole Capsule 150 mg

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

---

Each Ozole 150 mg capsule contains 150 mg of fluconazole.

### **Excipient(s) with known effect**

Contains lactose monohydrate. For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

---

OZOLE 150 mg is available for oral administration as a size 1 hard gelatin capsule with an opaque blue body and cap containing 150 mg fluconazole. The capsule is printed Ranbaxy on both cap and body.

## 4. CLINICAL PARTICULARS

---

### **4.1. Therapeutic indications**

OZOLE 150 mg Capsule, given orally, is indicated for vaginal candidiasis.

### **4.2. Dose and method of administration**

OZOLE 150 mg Capsule is administered orally.

### **Dose**

#### ***Use in Adults***

For vaginal candidiasis, fluconazole should be administered as a single oral dose.

The median time to onset of symptom relief following a 150 mg single oral dose for the treatment of vaginal candidiasis is one day. The range of time to onset of symptom relief is one hour to nine days.

#### ***Use in children***

Single-dose fluconazole is not recommended for use in children under 18 years of age except under doctor supervision.

## ***Special populations***

### **Use in Patients with Renal impairment**

Fluconazole is predominantly excreted in the urine as unchanged drug. No adjustments in single-dose therapy are necessary in patients with minor to moderate renal impairment.

### **4.3. Contraindications**

Fluconazole should not be used in patients with known sensitivity to fluconazole; to related azole compounds; or any of its excipients.

Co-administration of other drugs known to prolong the QT interval, and which are metabolised via the enzyme CYP3A4 such as cisapride, astemizole, erythromycin, pimozide and quinidine are contraindicated (refer to section 4.4).

Coadministration of terfenadine is contraindicated in patients receiving fluconazole at multiple doses of 400 mg per day or higher based upon results of a multiple-dose interaction study.

### **4.4. Special warnings and precautions for use**

Fluconazole should be administered with caution to patients with liver dysfunction.

Fluconazole has been associated with rare cases of serious hepatic toxicity including fatalities, primarily in patients with serious underlying medical conditions. In cases of fluconazole-associated hepatotoxicity, no obvious relationship to total daily dose, duration of therapy, sex or age of the patient has been observed. Fluconazole should not be used again if clinical signs and symptoms consistent with liver disease develop that may be attributable to fluconazole (refer to section 4.8).

Patients have rarely developed exfoliative cutaneous reactions, such as Stevens-Johnson Syndrome and toxic epidermal necrolysis, during treatment with fluconazole. AIDS patients are more prone to the development of serious cutaneous reactions to many medicines. Fluconazole should not be used again if a rash develops which is attributable to fluconazole.

In rare cases, as with other azoles, anaphylaxis has been reported.

Some azoles, including fluconazole, have been associated with prolongation of the QT interval on the electrocardiogram. Fluconazole causes QT prolongation via the inhibition of Rectifier Potassium Channel current (IKr). The QT prolongation caused by other medicinal products (such as amiodarone) may be amplified via the inhibition of cytochrome P450 (CYP) 3A4 (see section 4.5). During post-marketing surveillance, there have been very rare cases of QT prolongation and torsades de pointes in patients taking fluconazole. These reports included seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities and concomitant medications that may have been contributory (refer to section 4.8). Patients with hypokalaemia and advanced cardiac failure are at an increased risk for the occurrence of life-threatening ventricular arrhythmias and torsades de pointes.

The coadministration of fluconazole at doses lower than 400 mg per day with terfenadine should be carefully monitored.

Fluconazole is a potent CYP2C9 inhibitor and a moderate CYP3A4 inhibitor. Fluconazole treated patients who are concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9, CYP2C19 and CYP3A4 should be monitored. (see section 4.5).

Fluconazole should be administered with caution to patients with these potentially proarrhythmic conditions (refer to section 4.8).

Adrenal insufficiency has been reported in patients receiving other azoles (e.g., ketoconazole).

Reversible cases of adrenal insufficiency were reported in patients receiving fluconazole.

Ozole 150 mg capsules contain lactose and should not be given to patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.

#### **4.5. Interaction with other medicines and other forms of interaction**

**The relevance of the following medicine interactions to single-dose fluconazole is unknown. Patients on other medications should be advised to consult their doctor or pharmacist before starting fluconazole.**

Fluconazole is an inhibitor of the cytochrome P450 system, particularly the CYP 2C and to a lesser extent the CYP 3A isoforms. There are possibilities that other medicines may affect the metabolism of fluconazole and that fluconazole may affect the metabolism of other medicines. *In vitro* studies conducted in human hepatic microsomes, demonstrate that the extent of inhibition of CYP 3A isoforms is lowest with fluconazole, when compared with ketoconazole and itraconazole.

Fluconazole is a potent inhibitor of cytochrome P450 (CYP) isoenzymes 2C9 and 2C19 and a moderate inhibitor of CYP3A4. In addition to the observed/documentated interactions mentioned below, there is a risk of increased plasma concentration of other compounds metabolized by CYP2C9, CYP2C19 and CYP3A4 co-administered with fluconazole. Therefore, caution should be exercised when using these combinations and the patients should be carefully monitored. The enzyme inhibiting effect of fluconazole persists 4 to 5 days after discontinuation of fluconazole treatment due to the long half-life of fluconazole (refer to section 4.3).

#### **Alfentanil**

A study observed a reduction in clearance and distribution volume as well as prolongation of T<sub>1/2</sub> of alfentanil following concomitant treatment with fluconazole. A possible mechanism of action is fluconazole's inhibition of CYP3A4. Dosage adjustment of alfentanil may be necessary.

### **Amiodarone**

Concomitant administration of fluconazole with amiodarone may increase QT prolongation. Caution must be exercised if the concomitant use of fluconazole and amiodarone is necessary, notably with high dose fluconazole (800 mg).

### **Amitriptyline, nortriptyline**

Fluconazole increases the effect of amitriptyline and nortriptyline. 5-nortriptyline and/or S-amitriptyline may be measured at initiation of the combination therapy and after one week. Dosage of amitriptyline/nortriptyline should be adjusted, if necessary.

### **Amphotericin B**

Concurrent administration of fluconazole and amphotericin B in infected normal and immunosuppressed mice showed the following results: a small additive antifungal effect in systemic infection with *C. albicans*, no interaction in intracranial infection with *Cryptococcus neoformans*, and antagonism of the two drugs in systemic infection with *A. fumigatus*. The clinical significance of results obtained in these studies is unknown.

### **Anticoagulants**

In an interaction study, fluconazole increased the prothrombin time (12%) after warfarin administration in healthy males. In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, haematuria, and melena) have been reported, in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. Prothrombin time in patients receiving coumarin-type anticoagulants should be carefully monitored. Dose adjustment of warfarin may be necessary.

### **Astemizole**

Concomitant administration of fluconazole with astemizole may decrease the clearance of astemizole. Resulting increased plasma concentrations of astemizole can lead to QT prolongation and rare occurrences of *torsade de pointes*. Coadministration of fluconazole and astemizole is contraindicated (refer to section 4.3).

### **Azithromycin**

An open-label, randomised, three-way crossover study in 18 healthy subjects assessed the effect of a single 1200 mg oral dose of azithromycin on the pharmacokinetics of a single 800 mg oral dose of fluconazole as well as the effects of fluconazole on the pharmacokinetics of azithromycin. There was no significant interaction between fluconazole and azithromycin.

### **Carbamazepine**

Fluconazole inhibits the metabolism of carbamazepine and an increase in serum carbamazepine of 30% has been observed. There is a risk of developing carbamazepine toxicity. Dosage

adjustment of carbamazepine may be necessary depending on concentration measurements/effect.

### **Calcium channel blockers**

Certain calcium channel antagonists (nifedipine, isradipine, amlodipine, verapamil and felodipine) are metabolized by CYP3A4. Fluconazole has the potential to increase the systemic exposure of the calcium channel antagonists. Frequent monitoring for adverse events is recommended.

### **Celecoxib**

During concomitant treatment with fluconazole (200 mg daily) and celecoxib (200 mg) the celecoxib  $C_{max}$  and AUC increased by 68% and 134%, respectively. Half of the celecoxib dose may be necessary when combined with fluconazole.

### **Cyclophosphamide**

Combination therapy with cyclophosphamide and fluconazole results in an increase in serum bilirubin and serum creatinine. The combination may be used while taking increased consideration to the risk of increased serum bilirubin and serum creatinine.

### **Erythromycin**

Concomitant use of fluconazole and erythromycin has the potential to increase the risk of cardiotoxicity (prolonged QT interval, torsades de pointes) and consequently sudden heart death. Coadministration of fluconazole and erythromycin is contraindicated (refer to section 4.3).

### **Fentanyl**

One fatal case of possible fentanyl fluconazole interaction was reported. The author judged that the patient died from fentanyl intoxication. Furthermore, in a randomized crossover study with twelve healthy volunteers, it was shown that fluconazole delayed the elimination of fentanyl significantly. Elevated fentanyl concentration may lead to respiratory depression.

### **Halofantrine**

Fluconazole can increase halofantrine plasma concentration due to an inhibitory effect on CYP3A4.

### **HMG-CoA reductase inhibitors**

The risk of myopathy and rhabdomyolysis increases when fluconazole is co-administered with HMG-CoA reductase inhibitors metabolised through CYP3A4, such as atorvastatin and simvastatin, or through CYP2C9, such as fluvastatin. If concomitant therapy is necessary, the patient should be observed for symptoms of myopathy and rhabdomyolysis and creatine kinase should be monitored. HMG-CoA reductase inhibitors should be discontinued if a marked increase in creatine kinase is observed or myopathy/rhabdomyolysis is diagnosed or suspected.

### **Hydrochlorothiazide**

Concomitant oral administration of 100 mg fluconazole and 50 mg hydrochlorothiazide for 10 days in normal volunteers resulted in an increase of 41% in  $C_{max}$  and an increase of 43% in AUC of fluconazole, compared to fluconazole given alone. An effect of this magnitude should not necessitate a change in the fluconazole dose regimen in subjects receiving diuretics, although the prescriber should bear it in mind.

### **Rifampicin**

Administration of a single oral 200 mg dose of fluconazole after chronic rifampicin administration resulted in a 25% decrease in AUC and a 20% shorter half-life of fluconazole in normal volunteers. Depending on clinical circumstances, an increase of the dose of fluconazole should be considered when it is administered with rifampicin.

### **Cisapride**

Cardiac events including torsades de pointes have been reported in patients receiving fluconazole and cisapride concomitantly. In most of these cases, the patients appear to have been predisposed to arrhythmias or had a serious underlying illness. A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval. Co-administration of cisapride is contraindicated in patients receiving fluconazole (refer to section 4.3).

### **Cyclosporin**

A kinetic study in renal transplant patients found fluconazole 200 mg daily to slowly increase cyclosporin concentrations. However, in another multiple-dose study with 100 mg daily, fluconazole did not affect cyclosporin levels in patients with bone marrow transplants. Cyclosporin plasma concentration monitoring in patients, with or without impaired renal function, receiving fluconazole is recommended.

### **Losartan**

Fluconazole inhibits the metabolism of losartan to its active metabolite (E- 31 74) which is responsible for most of the angiotensin II-receptor antagonism which occurs during treatment with losartan. Patients should have their blood pressure monitored continuously.

### **Methadone**

Fluconazole may enhance the serum concentration of methadone. Dosage adjustment of methadone may be necessary.

### **Non-steroidal anti-inflammatory drug (NSAIDs)**

The  $C_{max}$  and AUC of flurbiprofen were increased by 23% and 81%, respectively, when co-administered with fluconazole compared to administration of flurbiprofen alone. Similarly, the  $C_{max}$  and AUC of the pharmacologically active isomer [S-(+)-ibuprofen] were increased by 15% and 82%, respectively, when fluconazole was co-administered with racemic ibuprofen (400 mg) compared to administration of racemic ibuprofen alone.

Although not specifically studied, fluconazole has the potential to increase the systemic exposure of other NSAIDs that are metabolized by CYP2C9 (e.g. naproxen, lornoxicam, meloxicam, diclofenac). Frequent monitoring for adverse events and toxicity related to NSAIDs is recommended. Adjustment of dosage of NSAIDs may be needed.

### **Oral Contraceptives**

Three kinetic studies with a combined oral contraceptive have been performed using multiple doses of fluconazole. There were no relevant effects on either hormone level in the 50 mg fluconazole study, while at 200 mg daily the AUC's of ethinylestradiol and levonorgestrel were increased by 40% and 24% respectively. In a 300 mg once weekly fluconazole study, the AUC's of ethinylestradiol and norethindrone were increased by 24% and 13% respectively. Thus, multiple-dose use of fluconazole at these doses is unlikely to have an effect on the efficacy of the combined oral contraceptive.

### **Oral Hypoglycaemic Agents**

The effects of fluconazole on the pharmacokinetics of the sulphonylurea oral hypoglycaemic agents tolbutamide, glipizide and glibenclamide were examined in three placebo-controlled crossover studies in normal volunteers. All subjects received the sulphonylurea alone and following treatment with 100 mg of fluconazole as a single daily oral dose for 7 days. Fluconazole administration resulted in significant increases in  $C_{max}$  and AUC of the sulphonylurea. Several subjects in these three studies experienced symptoms consistent with hypoglycaemia. In the glibenclamide study, several volunteers required oral glucose treatment. As fluconazole is a potent inhibitor of CYP2C8 and CYP2C9, it may also interact with other sulphonylureas (e.g. glimepiride and gliclazide) and the thiazolidinediones (e.g. pioglitazone and rosiglitazone), which are metabolised by these enzymes. When fluconazole and sulphonylureas or thiazolidinediones are co-administered, blood glucose concentrations should be monitored carefully. The possibility of a hypoglycaemic episode should be borne in mind.

### **Phenytoin**

Concomitant administration of oral fluconazole (200 mg) with phenytoin at steady-state resulted in an average increase of 75% of phenytoin AUC values in normal volunteers. Careful monitoring of phenytoin concentrations in patients receiving fluconazole and phenytoin is recommended.

### **Pimozide**

Although not studied in vitro or in vivo, concomitant administration of fluconazole with pimozide may result in inhibition of pimozide metabolism. Increased pimozide plasma concentrations can lead to QT prolongation and rare occurrences of torsade de pointes. Co-administration of fluconazole and pimozide is contraindicated (refer to section 4.3).

### **Prednisone**

There was a case report that a liver-transplanted patient treated with prednisone developed acute adrenal cortex insufficiency when a three-month therapy with fluconazole was discontinued. The discontinuation of fluconazole presumably caused an enhanced CYP3A4 activity which led to increased metabolism of prednisone. Patients on long-term treatment with fluconazole and prednisone should be carefully monitored for adrenal cortex insufficiency when fluconazole is discontinued.

### **Quinidine**

Although not studied in vitro or in vivo, concomitant administration of fluconazole with quinidine may result in inhibition of quinidine metabolism. Use of quinidine has been associated with QT prolongation and rare occurrences of torsades de pointes. Co-administration of fluconazole and quinidine is contraindicated (refer to section 4.3).

### **Short Acting Benzodiazepines**

Studies in human subjects have reported changes in midazolam pharmacokinetics and clinical effects that are dependent on dosage and route of administration. Single doses of fluconazole 150 mg resulted in modest increases in midazolam concentrations and psychomotor effects following oral administration of 10 mg that may not be clinically significant. At doses used to treat systemic mycoses, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects following oral administration of midazolam 7.5 mg, but only modest increases that are not likely to be clinically significant following intravenous infusion of midazolam 0.05 mg/kg. If concomitant benzodiazepine therapy is necessary in patients being treated with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.

### **Rifabutin**

There have been reports that an interaction exists when fluconazole is administered concomitantly with rifabutin, leading to increased serum levels of rifabutin. There have been reports of uveitis in patients to whom fluconazole and rifabutin were co-administered. Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored.

### **Saquinavir**

Fluconazole increases the AUC of saquinavir with approximately 50%,  $C_{max}$  with approximately 55% and decreases the clearance of saquinavir with approximately 50% due to inhibition of

saquinavir's hepatic metabolism by CYP3A4 and inhibition of P-glycoprotein. Dosage adjustment of saquinavir may be necessary.

### **Sirolimus**

Fluconazole increases plasma concentrations of sirolimus presumably by inhibiting the metabolism of sirolimus via CYP3A4 and P-glycoprotein. This combination may be used with a dosage adjustment of sirolimus depending on the effect/concentration measurements.

### **Sulfonylureas**

Fluconazole has been shown to prolong the serum half-life of concomitantly administered oral sulfonylureas (e.g., chlorpropamide, glibenclamide, glipizide, tolbutamide) in healthy volunteers. Frequent monitoring of blood glucose and appropriate reduction of sulfonylurea dosage is recommended during coadministration.

### **Tacrolimus**

There have been reports that an interaction exists when fluconazole is administered concomitantly with tacrolimus, leading to increased serum levels of tacrolimus. There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were co-administered. Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored.

Fluconazole may increase the serum concentrations of orally administered tacrolimus up to 5 times due to inhibition of tacrolimus metabolism through CYP3A4 in the intestines. No significant pharmacokinetic changes have been observed when tacrolimus is given intravenously. Increased tacrolimus levels have been associated with nephrotoxicity. Dosage of orally administered tacrolimus should be decreased depending on tacrolimus concentration.

### **Terfenadine**

Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. One study at a 200 mg daily dose of fluconazole failed to demonstrate a prolongation in QTc interval. Another study at a 400 mg and 800 mg daily dose of fluconazole demonstrated that fluconazole taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated (see section 4.3). The coadministration of fluconazole at doses lower than 400 mg per day with terfenadine should be carefully monitored.

### **Theophylline**

In a placebo-controlled interaction study, the administration of fluconazole 200 mg for 14 days resulted in an 18% decrease in the mean plasma clearance of theophylline. Patients who are receiving high dose theophylline or who are otherwise at increased risk of theophylline toxicity should be observed for signs of theophylline toxicity while receiving fluconazole, and therapy modified appropriately if signs of toxicity develop.

### **Tofacitinib**

Exposure is increased when tofacitinib is co-administered with medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g. fluconazole). Dosage adjustment of tofacitinib may be necessary.

### **Triazolam**

Fluconazole increases the AUC of triazolam (single dose) by approximately 50%,  $C_{max}$  with 20-32% and increases  $t_{1/2}$  by 25-50 % due to the inhibition of metabolism of triazolam. Dosage adjustments of triazolam may be necessary.

### **Vinca Alkaloids**

Although not studied, fluconazole may increase the plasma levels of the vinca alkaloids (e.g., vincristine and vinblastine) and lead to neurotoxicity, which is possibly due to an inhibitory effect on CYP3A4.

### **Voriconazole (CYP2C9, CYP2C19 and CYP3A4 inhibitor)**

Concurrent administration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 2.5 days) and oral fluconazole (400 mg on day 1, then 200 mg Q24h for 4 days) to 6 healthy male subjects resulted in an increase in  $C_{max}$  and AUC, of voriconazole by an average of 57% (90% CI: 20%, 107%) and 79% (90% CI: 40%, 128%), respectively. In a follow-on clinical study involving 8 healthy male subjects, reduced dosing and/or frequency of voriconazole and fluconazole did not eliminate or diminish this effect. Concomitant administration of voriconazole and fluconazole at any dose is not recommended.

### **Vitamin A**

Based on case-report in one patient receiving combination therapy with all-trans-retinoid acid (an acid form of Vitamin A) and fluconazole, CNS related undesirable effects have developed in the form of pseudotumor cerebri, which disappeared after discontinuation of fluconazole treatment. This combination may be used but the incidence of CNS related undesirable effects should be borne in mind.

### **Warfarin**

A single dose of warfarin (15 mg) given to normal volunteers, following 14 days of orally administered fluconazole (200 mg) resulted in a 12% increase in the prothrombin time response (area under the prothrombin time-time curve). One of 13 subjects experienced a 2-fold increase in his prothrombin time response. In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, haematuria and melena) have been reported, in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. Careful monitoring of prothrombin time in patients receiving fluconazole and coumarin-type anticoagulants is recommended.

## **Zidovudine**

Fluconazole increases the  $C_{max}$  and AUC of zidovudine, respectively, due to a decrease in oral zidovudine clearance. The half-life of zidovudine was likewise prolonged following combination therapy with fluconazole. Patients receiving this combination should be monitored for the development of zidovudine-related adverse reactions. Dosage reduction of zidovudine may be considered.

## **Gastrointestinal Medicines**

In fasted normal volunteers, absorption of orally administered fluconazole does not appear to be affected by agents that increase gastric pH. Single-dose administration of fluconazole (100 mg) with cimetidine (400 mg) resulted in a 13% reduction in AUC and 21% reduction in  $C_{max}$  of fluconazole. Administration of an antacid containing aluminium and magnesium hydroxides immediately prior to a single dose of fluconazole (100 mg) had no effect on the absorption or elimination of fluconazole.

Physicians should be alert to the potential for interactions with other medicines for which pharmacokinetic interaction studies have not been conducted.

### **4.6. Fertility, pregnancy and lactation**

#### **Women of childbearing potential**

Fluconazole should not be used in women who are pregnant or in women of childbearing potential unless adequate contraception is employed.

#### **Pregnancy**

Category D

A study found any maternal exposure to fluconazole during pregnancy may increase the risk of spontaneous abortion and that doses higher than 150 mg during the first trimester may increase the risk of cardiac septal closure anomalies.

There are no adequate and well-controlled studies in pregnant women. There have been reports of multiple congenital abnormalities in infants whose mothers were being treated for 3 or more months with high dose (400-800 mg/day) fluconazole therapy for coccidioidomycosis. The relationship between fluconazole use and these events is unclear.

Adverse foetal effects have been seen in animals only at high dose levels associated with maternal toxicity (see section 5.3).

#### **Breast-feeding**

Fluconazole is found in human breast milk at concentrations similar to plasma, hence its use in nursing mothers is not recommended.

## **Fertility**

Fluconazole did not affect the fertility of male or female rats (see section 5.3).

### **4.7. Effects on ability to drive and use machines**

When driving vehicles or operating machines, it should be taken into account that occasionally dizziness or seizures may occur.

### **4.8. Undesirable effects**

Fluconazole is generally well tolerated.

In some patients, particularly those with serious underlying diseases such as AIDS and cancer, changes in renal and haematological function test results and hepatic abnormalities (refer to section 4.4) have been observed during treatment with fluconazole and comparative agents, but the clinical significance and relationship to treatment is uncertain.

The following undesirable effects have been observed and reported during treatment with fluconazole. Frequencies are defined as very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1,000$  to  $< 1/100$ ); rare ( $\geq 1/10,000$  to  $< 1/1,000$ ); very rare ( $< 1/10,000$ ), not known (cannot be estimated from the available data).

<b>System Organ Class</b>	<b>Frequency</b>	<b>Undesirable Effects</b>
<b>Blood and lymphatic system disorders</b>	Rare	Agranulocytosis, leukopenia, neutropenia, thrombocytopenia
<b>Immune system disorders</b>	Rare	Anaphylaxis
<b>Metabolism and nutrition disorders</b>	Rare	Hypercholesterolaemia, hypertriglyceridaemia, hypokalaemia
<b>Psychiatric disorders</b>	Uncommon	Insomnia, somnolence, nervousness, female sexual dysfunction
<b>Nervous system disorders</b>	Common	Headache
	Uncommon	Seizures, dizziness, paraesthesia, taste perversion, flushing, hyperkinesia, hypertonia
	Rare	Tremor
<b>Ear and labyrinth disorders</b>	Uncommon	Vertigo
<b>Cardiac disorders</b>	Rare	Torsade de pointes, QT prolongation (see section 4.4)
<b>Vascular disorders</b>	Uncommon	Hot flushes
<b>Gastrointestinal disorders</b>	Common	Abdominal pain, diarrhoea, nausea, vomiting, dyspepsia

	Uncommon	Flatulence, dry mouth, anorexia, constipation, loose stools
<b>Hepatobiliary disorders</b>	Common	Alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased
	Uncommon	Cholestasis, jaundice, bilirubin increased
	Rare	Hepatic toxicity, including rare cases of fatalities, hepatic failure, hepatocellular necrosis, hepatitis, hepatocellular damage
<b>Skin and subcutaneous tissue disorders</b>	Common	Rash
	Uncommon	Pruritus, urticaria, increased sweating, drug eruption, erythematous rash, dry skin, abnormal skin odour
	Rare	Angioedema, toxic epidermal necrolysis, Steven-Johnson syndrome, acute generalised exanthematous pustulosis, dermatitis exfoliative, face oedema, alopecia
	Not known	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
<b>Musculoskeletal and connective tissue disorders</b>	Uncommon	Myalgia, back pain
<b>Renal and urinary disorders</b>	Uncommon	Polyuria, renal pain
<b>Infections and infestations</b>	Uncommon	Pharyngitis, herpes simplex
<b>Reproductive system and breast disorders</b>	Uncommon	Intermenstrual bleeding, dysmenorrhoea, leucorrhoea, menorrhagia, uterine spasm, vaginal disorder genital pruritus
<b>Eye disorders</b>	Uncommon	Abnormal vision, visual field defect
<b>General disorder and administration site conditions</b>	Uncommon	Fatigue, malaise, asthenia, fever, pain, rigours, thirst

### **Paediatric population**

The pattern and incidence of adverse events and laboratory abnormalities recorded during paediatric clinical trials are comparable to those seen in adults.

### ***Reporting of suspected adverse reactions***

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected reactions <https://nzphvc.otago.ac.nz/reporting/>

### **4.9. Overdose**

The minimal lethal human dose has not been established. There have been case reports of overdosage with fluconazole and in one case, a 42-year-old patient infected with human immunodeficiency virus developed hallucinations and exhibited paranoid behaviour after reportedly ingesting 8,200 mg of fluconazole. The patient was admitted to the hospital, and his condition resolved within 48 hours.

In the event of overdosage, symptomatic treatment (with supportive measures and gastric lavage if necessary) should be undertaken.

Fluconazole is largely excreted in the urine; forced volume diuresis would probably increase the elimination rate. A three-hour haemodialysis session decreases plasma levels by approximately 50%.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

## **5. PHARMACOLOGICAL PROPERTIES**

---

### **5.1. Pharmacodynamic properties**

Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC code: J02AC01

Fluconazole is a member of the bis-triazole class of antifungal agents. Fluconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14 alpha demethylation. Mammalian cell demethylation is much less sensitive to fluconazole inhibition. The subsequent loss of normal sterols correlates with the accumulation of 14 alpha-methyl sterols in fungi and may be responsible for the fungistatic activity of fluconazole. Interaction studies with antipyrine indicate that single or multiple doses of fluconazole 50 mg do not affect its metabolism.

## 5.2. Pharmacokinetic properties

### **Pharmacokinetic and Metabolism**

In normal volunteers, the bioavailability of orally administered fluconazole is over 90% compared with intravenous administration. Oral administration is not affected by concomitant food intake. In fasted normal volunteers, peak plasma concentrations occur between 1- and 2-hours post-dose with a terminal plasma elimination half-life of approximately 30 hours (range 20 - 50 hours). The apparent volume of distribution approximates to total body water. Plasma protein binding is low (11 - 12%).

Fluconazole has been found to achieve good penetration into all tissues and body fluids studied. The levels of fluconazole in saliva and sputum are similar to plasma levels.

The major route of excretion is renal, with approximately 80% of the administered dose appearing in the urine as unchanged medicine. About 11% of the dose is excreted in the urine as metabolites. The pharmacokinetics of fluconazole are markedly affected by a reduction in renal function, however, no adjustments in single-dose therapy are necessary. There is an inverse relationship between the elimination half-life and creatinine clearance.

The long plasma elimination half-life provides the basis for single-dose therapy for vaginal candidiasis.

There are differences in the pharmacokinetics between adults and children, with children after the neonatal period generally having a faster elimination rate and larger volume of distribution than adults.

### **Microbiology**

Fluconazole administered orally or intravenously was active in a variety of animal models of fungal infections using standard laboratory strains of fungi.

Fluconazole exhibits *in vitro* activity against *Cryptococcus neoformans* and *Candida* spp. Activity has been demonstrated *in vivo* in normal and immunocompromised animals against infections with *Candida* spp., including systemic candidiasis and in normal animals with *C. neoformans*, including intracranial infections. One case of cross-resistance of *Candida* to fluconazole in a patient (non-HIV) previously treated with ketoconazole has been reported. The efficacy of fluconazole *in vivo* is greater than would be apparent from *in vitro* testing against the above-mentioned fungi.

Concurrent administration of fluconazole and amphotericin B in infected normal and immunocompromised mice showed antagonism of the two medicines in systemic infection with *Aspergillus fumigatus*. The clinical significance of results obtained in these studies is unknown.

### **5.3. Preclinical safety data**

#### **Mutagenesis**

Fluconazole, with or without metabolic activation, was negative in tests for mutagenicity in four strains of *Salmonella typhimurium* and in the mouse lymphoma system. Cytogenetic studies *in vivo* (murine bone marrow cells, following oral administration of fluconazole) and *in vitro* (human lymphocytes exposed to fluconazole at 1000 µ micrograms per mL) showed no evidence of chromosomal mutations.

#### **Carcinogenesis**

Fluconazole showed no evidence of carcinogenic potential in mice and rats treated orally for 24 months at doses of 2.5, 5 or 10 mg/kg/day (approximately 2 - 7 times the recommended human dose). Male rats treated with 5 and 10 mg/kg/day had an increased incidence of hepatocellular adenomas.

#### **Impairment of Fertility**

Fluconazole did not affect the fertility of male or female rats treated orally with daily doses of 5 mg/kg, 10 mg/kg or 20 mg/kg or with parenteral doses of 5 mg/kg, 25 mg/kg or 75 mg/kg, although the onset of parturition was slightly delayed at 20 mg/kg orally. In an intravenous perinatal study in rats at 5 mg/kg, 20 mg/kg and 40 mg/kg, dystocia and prolongation of parturition were observed in a few dams at 20 mg/kg (approximately 5 – 15 times the recommended human dose) and 40 mg/kg, but not at 5 mg/kg. The disturbances in parturition were reflected by a slight increase in the number of still-born pups and decrease of neonatal survival at these dose levels. The effects on parturition in rats are consistent with the species-specific oestrogen-lowering property produced by high doses of fluconazole. Such a hormone change has not been observed in women treated with fluconazole.

## **6. PHARMACEUTICAL PARTICULARS**

---

### **6.1. List of excipients**

The ingredients present inside OZOLE 150 mg capsules include lactose monohydrate, maize starch, sodium lauryl sulphate, colloidal anhydrous silica, and magnesium stearate. In addition, the capsules shells contain gelatin, patent blue (E133) and titanium dioxide (E171).

The black colour in the printing ink is black iron oxide (E172).

### **6.2. Incompatibilities**

Not applicable.

### **6.3. Shelf life**

36 months.

#### 6.4. Special precautions for storage

Store at or below 25°C.

#### 6.5. Nature and contents of container

OZOLE 150 mg capsule is available as a single treatment pack.

Blister pack, PVC/PVDC/Al foil.

#### 6.6. Special precautions for disposal and other handling

Any unused medicine or waste material should be disposed of in accordance with local requirements.

### 7. MEDICINE SCHEDULE

---

Restricted Medicine

### 8. SPONSOR

---

Douglas Pharmaceuticals Ltd

P O Box 45 027

Auckland 0651

New Zealand

Phone: (09) 835 0660

### 9. DATE OF FIRST APPROVAL

---

09 March 2006

### 10. DATE OF REVISION OF THE TEXT

---

18 September 2020

Summary table of changes

Section Changed	Summary of new information
4.6	Updated as per Medsafe Letter- Pregnancy exposure: <i>A study found any maternal exposure to fluconazole during pregnancy may increase the risk of spontaneous abortion and that doses higher than 150 mg during the first trimester may increase the risk of cardiac septal closure anomalies.</i>